|
FDA APPROVES FIRST GENE-BASED TEST, UROVYSIONTM, FOR DIAGNOSIS OF PATIENTS SUSPECTED OF HAVING BLADDER CANCER UroVysion shown to be more sensitive than established methods in detecting bladder cancer - Jan. 25, 2005, The U.S. Food and Drug Administration
Veripath OncoDiagnostics offers VysisŪ UroVysion Blander Cancer Fluorescence in-situ Hybridization for the detection of recurrence cancer. The UroVysion Kit is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in-situ hybridization (FISH) in urine specimens from subjects with transitional cell carcinoma of the bladder.
Results from the UroVysion Test are intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.
|
